Sparsentan

BNP Paribas Financial Markets reduced its stake in Ligand Pharmaceuticals by 27.6% during Q3. Several investors modified their holdings, with Woodstock Corp, Creative Planning, and Mirae Asset Global Investments increasing their positions. Insiders sold shares worth $2.27 million in the last quarter. LGND stock opened at $116.91, with a consensus rating of 'Buy' and an average target price of $145.33. Ligand Pharmaceuticals develops and licenses biopharmaceutical assets globally.

The Japanese Ministry of Health, Labour, and Welfare has granted orphan drug designation to Renalys Pharma’s sparsentan for primary IgA nephropathy. Sparsentan, developed by Travere Therapeutics, received FDA approval in September and is being advanced by Renalys Pharma in Japan and Asia. The therapy aims to address kidney function decline in IgA nephropathy, a leading cause of kidney failure in Japan.

The FDA has approved a Phase 2 trial for ruxoprubart, an anti-Bb monoclonal antibody targeting the alternative pathway for treating Immunoglobulin A nephropathy (IgAN). Ruxoprubart, developed by NovelMed, aims to improve clinical outcomes for IgAN patients, affecting 82,000-110,000 individuals in the US. The drug's selective pathway inhibition differentiates it from other complement blockers, potentially treating various renal disorders. NovelMed seeks strategic partners to advance ruxoprubart to Phase 2/3 trials.

The article discusses the importance of enabling JavaScript for optimal app performance.

IgA nephropathy affects 25-50 per million annually, with 20–40% progressing to end-stage kidney disease. Diagnosed cases in the US are expected to reach 135,000 by 2030. Treatments include ACE inhibitors, ARBs, corticosteroids, and immunosuppressants. FDA-approved treatments are TARPEYO, FILSPARI, and FABHALTA. The IgA nephropathy market is projected to reach ~USD 4.1 billion by 2034, driven by novel therapies like Novartis’ Atrasentan, Otsuka/Visterra’s Sibeprenlimab, Vertex/Alpine’s Povetacicept, and others.

Travere Therapeutics presented new data on FILSPARI (sparsentan) at ASN Kidney Week 2024, showing its effectiveness in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Key findings include rapid and sustained proteinuria reduction, significant complete remission rates in IgAN patients, and safety in combination therapies. The data also highlighted long-term kidney health benefits in genetic, treatment-resistant FSGS patients.